The presence of pulmonary infiltrates at diagnosis and the need for oxygen suggest poor outcomes. Current studies focused on patients with AML have confirmed that COVID-19 severity tends to increase in immunocompromised patients. Patients with AML are considered a high-risk population because of their immunocompromised status. Thus, continuous supportive treatment can lead to favorable outcomes, even in heavily immunocompromised patients. Close evaluation of stem cell donors and transplant candidates is also needed. Therefore, early diagnosis and supportive treatment may improve the prognosis of these patients. Īs COVID-19 is a serious disease during an early pandemic, allogeneic-SCT in AML patients is believed to be at a particular risk for poor outcomes due to an immunocompromised state. Constant hygiene measures may further help save patients during the COVID-19 pandemic. Therefore, consistent polymerase chain reaction (PCR) and IgG antibody tests are mandatory for safely performing allogeneic-SCT. The clinical course of COVID-19 in patients with AML is unusual. The COVID-19 pandemic presents great challenges for allogeneic-SCT. Allogeneic stem cell transplant (SCT) remains the best treatment option for patients with intermediate- or high-risk AML. AML patients are at high risk for coronavirus disease (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) due to an immunocompromised state.
0 kommentar(er)
